Biopsy- and biology-driven optimization of targeted therapy of metastatic melanoma in BRAF inhibitor non-pretreated and pretreated subjects with advanced, non-resectable (Stage IIIC) or metastatic (Stage IV) BRAF V600E/K mutation-positive melanoma

To broaden the understanding of molecular characterization of the melanoma in correlation to the clinical response (defined as partial response according to RECIST) at week 8 of targeted therapy (GSK2118436 (BRAFi) versus GSK2118436 (BRAFi) and GSK1120212 (MEKi)) for subjects with advanced/metastatic BRAF V600E/K mutation-positive cutaneous melanoma